Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: Considerations for future drug discovery

Current Opinion in Lipidology

Volumn 21, Issue 3, 2010, Pages 192-197

  Brown, J Mark ^a   Rudel, Lawrence L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammation; Metabolic syndrome; Saturated fatty acids; Stearoyl CoA desaturase

Indexed keywords

ACYL COENZYME A DESATURASE 1; ACYL COENZYME A DESATURASE 1 INHIBITOR; ENZYME INHIBITOR; MONOUNSATURATED FATTY ACID; SATURATED FATTY ACID; UNCLASSIFIED DRUG;

APOPTOSIS; ATHEROSCLEROSIS; COLITIS; CYTOTOXICITY; DISEASE EXACERBATION; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; FATTY LIVER; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPIDOSIS; LIPOTOXICITY; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; STEAROYL-COA DESATURASE;

RODENTIA;

EID: 77952426387     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32833854ac     Document Type: Review

References (67)

1. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110:1245-1250.
2. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752.
3. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28:629-636.
4. Cohen P, Ntambi JM, Friedman JM. Stearoyl-CoA desaturase-1 and the metabolic syndrome. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3:271-280.
5. Dobrzyn A, Ntambi JM. Stearoyl-CoA desaturase as a new drug target for obesity treatment. Obes Rev 2005; 6:169-174.
6. Miyazaki M, Ntambi JM. Role of stearoyl-coenzyme A desaturase in lipid metabolism. Prostaglandins Leukot Essent Fatty Acids 2003; 68:113-121.
7. Christy RJ, Yang VW, Ntambi JM, et al. Differentiation-induced gene expression in 3T3-L1 preadipocytes: CCAAT/enhancer binding protein interacts with and activates the promoters of two adipocyte-specific genes. Genes Dev 1989; 3:1323-1335.
8. Miyazaki M, Kim YC, Gray-Keller MP, et al. The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J Biol Chem 2000; 275:30132-30138.
9. Asilmaz E, Cohen P, Miyazaki M, et al. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J Clin Invest 2004; 113:414-424.
10. Miyazaki M, Dobrzyn A, Man WC, et al. Stearoyl-CoA desaturase 1 gene expression is necessary for fructose-mediated induction of lipogenic gene expression by sterol regulatory element-binding protein-1c-dependent and independent mechanisms. J Biol Chem 2004; 279:25164-25171.
11. Miyazaki M, Dobrzyn A, Sampath H, et al. Reduced adiposity and liver steatosis by stearoyl-CoA desaturase deficiency are independent of peroxisome prolif-erators-activated receptor-alpha. J Biol Chem 2004; 279:35017-35024.
12. Miyazaki M, Flowers MT, Sampath H, et al. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab 2007; 6:484-496.
13. Brown JM, Chung S, Sawyer JK, et al. Inhibition of stearoyl-coenzyme A desaturase 1 dissociates insulin resistance and obesity from atherosclerosis. Circulation 2008; 118:1467-1475.
14. Brown JM, Chung S, Sawyer JK, et al. Combined therapy of dietary fish oil and stearoyl-CoA desaturase 1 inhibition prevents the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol [Epub ahead of print].
15. Attie AD, Krauss RM, Gray-Keller MP, et al. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyeridemia. J Lipid Res 2002; 43:1899-1907.
16. Chu K, Miyazaki M, Man WC, Ntambi JM. Stearoyl-coenzyme A desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activation. Mol Cell Biol 2006; 26:6786-6798.
17. Ntambi JM, Miyazaki M, Stoehr JP, et al. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci USA 2002; 99:11482-11486.
18. Cohen P, Miyazaki M, Socci ND, et al. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 2002; 297:240-243.
19. Gutierrez-Juarez R, Pocai A, Mulas C, et al. Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J Clin Invest 2006; 116:1686-1695.
20. Macdonald ML, Singaraja RR, Bissada N, et al. Absence of stearoyl-CoA desaturase-1 ameloriates features of the metabolic syndrome in LDLR-defi-cient mice. J Lipid Res 2008; 49:217-229.
21. Flowers JB, Rabaglia ME, Schueler KL, et al. Loss of stearoyl-CoA desaturase-1 improves insulin sensitivity in lean mice but worsens diabetes in leptin-deficient obese mice. Diabetes 2007; 56:1228-1239.
22. Rahman SM, Dobrzyn A, Lee SH, et al. Stearoyl-CoA desaturase 1 deficiency increases insulin signaling and glycogen accumulation in brown adipose tissue. Am J Physiol Endocrinol Metab 2005; 288:E381-387.
23. Rahman SM, Dobrzyn A, Dobrzyn P, et al. Stearoyl-CoA desaturase 1 deficiency elevates insulin-signaling components and down-regulates pro-tein-tyrosine phosphate 1B in muscle. Proc Natl Acad Sci USA 2003; 100:11110-11115.
24. Jiang G, Li Z, Liu F, et al. Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J Clin Invest 2005; 115:1030-1038.
25. Flowers MT, Groen AK, Oler AT, et al. Cholestasis and hypercholesterolemia in SCD1-deficient mice fed a low-fat, high-carbohydrate diet. J Lipid Res 2006; 47:2668-2680.
26. Xu H, Wilcox D, Nguyen P, et al. Hepatic knockdown of stearoyl-CoA desaturase 1 via RNA interference in obese mice decreases lipid content and changes fatty acid composition. Front Biosci 2007; 12:3781-3794.
27. Yahagi N, Shimano H, Hasegawa K, et al. Coordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer 2005; 41:1316-1322.
28. Scaglia N, Caviglia JM, Igal RA. High stearoyl-CoA desaturase protein and activity levels in simian virus 40transformed-human lung fibroblasts. Biochem Biophys Acta 1687:141-151.
29. Li J, Ding SF, Habib NA, et al. Partial characterization of a cDNA for human stearoyl-CoA desaturase and changes in its mRNA expression in some normal and malignant tissues. Int J Cancer 1994; 57:348-352.
30. Lu J, Pei H, KaeckM, et al. Gene expression changes associated with chemically induced rat mammary carcinogenesis. Mol Carcinog 1997; 20:204-215.
31. Thai SF, Allen JW, DeAngelo AB, et al. Detection of early gene expression changes by differential display in the livers of mice exposed to dichloroacetic acid. Carcinogenesis 2001; 22:1317-1322.
32. Kumar-Sinha C, Ignato KW, Lippman ME, et al. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 2003; 63:132-139.
33. Morgan-Lappe SE, Tucker LA, Huang X, et al. Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res 2007; 67:4390-4398.
34. Scaglia N, Igal RA. Stearoyl-CoA desaturase is involved in the control of proliferation, anchorage-independent growth, and survival in human transformed cells. J Biol Chem 2005; 25339-25349.
35. Scaglia N, Igal RA. Inhibition of stearoyl-CoA desaturase 1 expression in human lung adenocarcinoma cells impairs tumorigenesis. Int J Oncol 2008; 33:839-850.
36. Scaglia N, Chisholm J, Igal RA. Inhibition of stearoyl-CoA desaturase-1 inactivates acetyl-CoA carboxylase and impairs proliferation in cancer cells: role of AMPK. PLoS One 2009; 4:e6812.
37. Miyazaki M, Man WC, Ntambi JM. Targeted disruption of stearoyl-CoA desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid. J Nutr 2001; 131:2260-2268.
38. Sundberg JP, Boggess D, Sundberg BA, et al. Asebia-2J (Scd1(ab2J)): a new allele and a model forscarring alopecia. Am J Path 2000; 156:2067-2075.
39. Zheng Y, Eilertsen KJ,Ge L, et al. Scd1 is expressed in sebaceous glands and is disrupted in the asebia mouse. Nat Genet 1999; 23:268-270.
40. Lee SH, Dobrzyn A, Dobrzyn P, et al. Lack of stearoyl-CoA desaturase 1 upregulates basal thermogenesis but causes hypothermia in a cold environment. J Lipid Res 2004; 45:1674-1682.
41. Binczek E, Jenke B, Holz B, et al. Obesity resistance of the stearoyl-CoA deficient (scd1-/-) mouse results from disruption of the epidermal lipid barrier and adaptive thermoregulation. Biol Chem 2007; 388:405-418.
42. Sampath H, Flowers MT, Liu X, et al. Skin-specific deletion of stearoyl-CoA desaturase-1 alters skin lipid composition and protects mice from high fat diet-induced obesity. J Biol Chem 2009; 284:19961-19973.
43. Rudel LL, Haines J, Sawyer JK, et al. Hepatic origin of cholesteryl oleate in coronary artery atherosclerosis in African green monkeys. Enrichment by dietary monounsaturated fat. J Clin Invest 1997; 100:74-83.
44. Willner E, Tow B, Buhman KK, et al. Deficiency of acyl-CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 2003; 100:1262-1267.
45. Lee RG, Kelley KK, Sawyer JK, et al. Plasma cholesterol esters provided by lecithin:cholesterol acyltransferase and acyl-CoA:cholesterol acyltransferase have opposite atherosclerostic potential. Circ Res 2004; 95:998-1004.
46. MacDonald ML, van Eck M, Hildebrand RB, et al. Despite antiatherogenic metabolic characteristics, SCD1-deficient mice have increased inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29:341-347.
47. Lupi R, Dotta F, Marselli L, et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on humans pancreatic islets: evidence that ß-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl2 regulated. Diabetes 2002; 51:1437-1442.
48. ShimabukuroM,Zhou YT, Levi M, et al. Fatty acid-induced betacellapoptosis:a link between obesity and diabetes. Proc Natl Acad Sci USA 1998; 95: 2498-2502.
49. Maedler K, Oberholzer J, Bucher P, et al. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic ß-cell turnover and function. Diabetes 2003; 52:726-733.
50. PiroS, Anello M, Di PietroC, et al. Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. Metabolism 2002; 51:1340-1347.
51. Maestre I, Jordan J, Calvo S, et al. Mitochondrial dysfunction is involved in apoptosis induced by serum withdrawal and fatty acids in the beta-cell line INS-1. Endocrinology 2003; 144:335-345.
52. El-Assaad W, Buteau J, Peyot ML, et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 2003; 144:4154-4163.
53. Busch AK, Gurisik E, Cordery DV, et al. Increased fatty acid desaturation and enhanced expression of stearoyl coenzyme A desaturase protects pancreatic beta cells from lipoapoptosis. Diabetes 2005; 54:2917-2924.
54. Hellemans KH, Hanaert JC, Denys B, et al. Susceptibility of pancreatic beta cells to fatty acids is regulated by LXR/PPARalpha-dependent stearoyl-coenzyme A desaturase. PLoS One 2009; 4:e7226.
55. Chen C, Shah YM, Morimura K, et al. Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab 2008; 7:135-147.
56. MacDonald ML, Bissada N, Vallance BA, et al. Stearoyl-CoA desaturase-1 does not promote DSS-induced acute colitis. Biochem Biophys Acta 2009; 1791:1166-1172.
57. Li ZZ, Berk M, McIntyre TM, et al. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease. J Biol Chem 2009; 284:5637-5644.
58. Temel RE, Rudel LL. Diet effects on atherosclerosis in mice. Curr Drug Targets 2007; 8:1150-1160.
59. Gentile CL, Pagliassotti MJ. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 2008; 19:567-576.
60. Pickens MK, Yan JS, Ng RK, et al. Dietary sucrose is essential to the development of liver injury in the MCD model of steatohepatitis. J Lipid Res 2009 [Epub ahead of print].
61. Esteve M, Navarro E, Klaassen J, et al. Plasma and mucosal fatty acid pattern in colectomized ulcerative colitis patients. Dig Dis Sci 1998; 43:1071-1078.
62. Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116:3015-3025.
63. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 2001; 276:16683-16689.
64. Suganami T, Tanimoto-Koyama K, Nishida J, et al. Role of the Toll-like receptor4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 2007; 27:84-91.
65. Lee JY, Zhao L, Youn HS, et al. Saturated fatty acid activates but polyunsa-turated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem 2004; 279:16971-16979.
66. Lee JY, Ye J, Gao Z, et al. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem 2003; 278: 37041-37051.
67. Lee JY, Plakidas A, Lee WH, et al. Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res 2003; 44:479-486.